The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. TAIPEI and SAN DIEGO , Jan. About Silmitasertib. An eIND was granted by the U.S.

Trials 52

Trials Treatment Small Molecule Hospitals 52

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . billion, compared to $19.9 Tuyen Ong, MD, CEO, Ring Therapeutics. .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

MARCH 24, 2021

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus. Outlook 2021: slight year-on-year increase in net sales on a comparable basis. Medicines for the treatment of cardiovascular and metabolic diseases, as well as respiratory diseases, remain the most important contributors to net sales.

Vaccine 52

Vaccine Small Molecule Disease Therapies 52

The Pharma Data

JANUARY 19, 2021

20, 2021 03:41 UTC. Closing of the offering is expected to occur on or about January 22, 2021, subject to customary closing conditions. Syros is redefining the power of small molecules to control the expression of genes. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

APRIL 27, 2021

All doses expected to be delivered in 2021. NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

JULY 7, 2023

Approximately three percent of the global population — 240 million people — experience autoantibody diseases, which occur when one’s own body attacks critical organs and tissues. Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

JULY 21, 2021

Pfizer and BioNTech expect that Biovac’s Cape Town facility will be incorporated into the vaccine supply chain by the end of 2021. We believe that our mRNA technology can be used to develop vaccine candidates addressing other diseases as well. CEO and Co-founder of BioNTech. “We AUTHORIZED USE IN THE U.S.:

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

billion doses by the end of 2021. BNT162b2 encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), which is the target of virus neutralizing antibodies. billion doses by the end of 2021. billion doses by the end of 2021. About the Phase 2/3 Study. About BioNTech.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

MAY 7, 2021

Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The information contained in this release is as of May 7, 2021. AUTHORIZED USE IN THE U.S.:

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

MAY 6, 2021

Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The information contained in this release is as of May 6, 2021. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 11, 2020

Government to supply doses in 2020 & 2021. In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021. immediately, with delivery fulfillment expected to be completed in 2021.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Discovery World

FEBRUARY 2, 2023

Since inflammation underlies so many diseases and conditions, RRx-001, as an NLRP3 inflammasome inhibitor 1 , which turns off or turns down inflammation, is broadly protective. A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Pharma Data

AUGUST 20, 2020

billion doses by the end of 2021. We are proud to share our findings with the scientific community as we continue our work to deliver a safe and effective vaccine to combat this devastating virus,” said Kathrin U. billion doses by the end of 2021. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA FDA Approval 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

DECEMBER 10, 2020

These pivotal data demonstrate that our COVID-19 vaccine candidate is highly effective in preventing COVID-19 disease and is generally well-tolerated. The study also will explore prevention of infection by SARS-CoV-2, the virus that causes COVID-19. Secondary endpoints include prevention of severe COVID-19 in those groups.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

OCTOBER 26, 2020

V590 — a SARS-CoV-2 vaccine candidate in development in collaboration with the International AIDS Vaccine Initiative (IAVI) that uses a recombinant vesicular stomatitis virus (rVSV) platform, the same platform used for Merck’s approved Ebola Zaire virus vaccine, will enter Phase 1 development shortly.

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

OCTOBER 14, 2020

Results from the PRECISION Study Expected in First Half of 2021. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., The research encompasses two projects.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”.

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

The Pharma Data

DECEMBER 23, 2020

It’s almost 2021, and the whole world just wants to move on from COVID-19. While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s

FDA 52

FDA Small Molecule Clinical Trials Trials 52

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. It hopes to include more than 4,000 people in additional trials, with a possible regulatory approval by the fourth quarter of 2021. Odronextamab is a CD20xCD3 bispecific antibody.

Vaccine 52

Vaccine Trials Small Molecule Therapies 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals.

DNA 52

DNA RNA Engineering Licensing 52

Codon

JUNE 11, 2024

But these little machines, small enough to fit inside a pocket, have become commonplace. Biologists use nanopores for everything from diagnosing diseases and monitoring changes within rainforest ecosystems to discovering proteins from microbes frozen in Icelandic glaciers. Trends in Genetics (2021). Credit: Wan Y.K.

DNA 73

DNA Engineering RNA Small Molecule 73

The Pharma Data

SEPTEMBER 9, 2020

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. billion doses by the end of 2021. Argentina and Brazil. About BioNTech.

Vaccine 52

Vaccine RNA Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 15, 2020

Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). Rare Disease. BNT162 mRNA-based Vaccine Program. for RSV A and 18.0

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

DECEMBER 5, 2020

Syros will also present new translational data demonstrating that most RARA-positive newly diagnosed unfit AML patients have a monocytic disease phenotype that is highly correlated with resistance to upfront treatment with venetoclax and azacitidine. Syros expects to initiate the Phase 3 trial in the first quarter of 2021.

Clinical Trials 52

Clinical Trials Trials Small Molecule Pharmaceuticals 52

The Pharma Data

APRIL 7, 2021

The Prescription Drug User Fee Act (PDUFA) goal date has been extended three months to early Q3 2021. Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. About Abrocitinib.

Treatment 52

Treatment Clinical Trials Therapies Vaccine 52

The Pharma Data

JULY 21, 2021

As communicated on April 7, 2021, the FDA had previously extended the PDUFA goal dates to early Q3 2021. ?. Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease.

FDA 52

FDA Clinical Trials Treatment Therapies 52

Drug Target Review

FEBRUARY 15, 2024

Since the 20 th century, all known viral pandemics, including HIV, influenza, SARS CoV-1, SARS, CoV-1, and mpox, have resulted from a virus ‘spilling over’ from animals into humans. For example, scientists cannot accurately predict which town or village will have the next Nipah virus outbreak.

Drug Development 122

Drug Development Virus Vaccine Government 122

The Pharma Data

MARCH 11, 2021

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Programming inactive RNA-binding small molecules into bioactive degraders. Nature Chemical Biology. Nature Biotechnology.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Read Programming inactive RNA-binding small molecules into bioactive degraders. Nature Chemical Biology. Nature Biotechnology.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

JUNE 24, 2021

government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022. Deliveries of the 200 million doses will begin in August 2021 and continue through the remainder of the year. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S.

Government 52

Government Vaccine Clinical Trials Licensing 52